Literature DB >> 14748058

HIV epidemic in Central African Republic: high prevalence rates in both rural and urban areas.

Marcelle Diane Matsika-Claquin1, Marcel Massanga, Didier Ménard, Jean Mazi-Nzapako, Jean-Pierre Ténegbia, Marie-Joëlle Mandeng, Jean Willybiro-Sacko, Arnaud Fontanet, Antoine Talarmin.   

Abstract

A sentinel serosurveillance study was conducted in Central African Republic to estimate the prevalence of HIV seropositivity in the general adult population in each province so that the public health authorities can target HIV prevention programmes to the priority areas. Blood samples were collected from women attending 48 antenatal clinics in urban and rural areas of the Central African Republic. These samples were tested for HIV antibodies in an anonymous and unlinked manner using strategy II recommended by WHO. The data were extrapolated to all women of reproductive age in Central African Republic by use of a parity-based adjustment involving the application of correction factors to the observed prevalence rates. A total of 9,305 pregnant women were recruited from November 2001 to October 2002. HIV seroprevalence was high in all age groups (12% in the less than 20 year age group to 17% in the 25-29 year age group). The median prevalence of HIV in antenatal clinics was similar for rural areas, for Bangui and for other urban areas (16.5, 15.0, and 12.5% respectively). Adjustment for parity and fertility pattern increased the prevalence of HIV in all antenatal clinics except in Bangui. This first national study of HIV prevalence in Central African Republic revealed that the HIV epidemic is continuing to spread in both urban and rural areas. Thus, efforts to reduce transmission should be made in every part of the country. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14748058     DOI: 10.1002/jmv.20001

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Poor performance of a novel serological test for diagnosis of pulmonary tuberculosis in Bangui, Central African Republic.

Authors:  Eric Kassa-Kelembho; Edith Kassa; Germain Zandanga; Yves-Brillant Service; Albert Ignaleamoko; Antoine Talarmin
Journal:  Clin Vaccine Immunol       Date:  2006-06

2.  Clinical and epidemiological aspects of a hepatitis E outbreak in Bangui, Central African Republic.

Authors:  Alice I Goumba; Xavier Konamna; Narcisse P Komas
Journal:  BMC Infect Dis       Date:  2011-04-14       Impact factor: 3.090

3.  Human herpesvirus 8 serological markers and viral load in patients with AIDS-associated Kaposi's sarcoma in Central African Republic.

Authors:  Renan Duprez; Eric Kassa-Kelembho; Sabine Plancoulaine; Josette Brière; Mireille Fossi; Léon Kobangue; Pierre Minsart; Michel Huerre; Antoine Gessain
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.

Authors:  C Barassi; E Soprana; C Pastori; R Longhi; E Buratti; F Lillo; C Marenzi; A Lazzarin; A G Siccardi; L Lopalco
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans.

Authors:  Evélyne Bégaud; Loïc Chartier; Valéry Marechal; Julienne Ipero; Josianne Léal; Pierre Versmisse; Guillaume Breton; Arnaud Fontanet; Corinne Capoulade-Metay; Hervé Fleury; Françoise Barré-Sinoussi; Daniel Scott-Algara; Gianfranco Pancino
Journal:  Retrovirology       Date:  2006-06-22       Impact factor: 4.602

6.  Current tuberculin reactivity of schoolchildren in the Central African Republic.

Authors:  Fanny Minime-Lingoupou; Rock Ouambita-Mabo; Aristide-Désiré Komangoya-Nzozo; Dominique Senekian; Lucien Bate; François Yango; Bachir Nambea; Alexandre Manirakiza
Journal:  BMC Public Health       Date:  2015-05-17       Impact factor: 3.295

7.  Emergency preparedness and public health systems lessons for developing countries.

Authors:  Margaret E Kruk
Journal:  Am J Prev Med       Date:  2008-06       Impact factor: 5.043

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.